genedrive plc
("genedrive" or the "Company")
Notice of Results
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2020 on Thursday, 25 March 2021.
For further details please contact:
| genedrive plc | +44 (0)161 989 0245 |
| David Budd: CEO / Matthew Fowler: CFO | |
| | |
| Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 |
| James Steel / Oliver Jackson | |
| | |
| finnCap (Joint Broker) | +44 (0)20 7220 0500 |
| Geoff Nash / Kate Bannatyne / Alice Lane | |
| | |
| Walbrook PR Ltd (Media & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
| Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 |
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
